Cibus: Pursuing a better sustained release

For sustained release drugs that are no longer patent protected, or for those that will soon go off patent, as well as for those that lack significant generic competition, Cibus Pharmaceutical Inc. is stepping in with a technology that the company believes can produce bioequivalence cheaper, faster and with a more flexible release profile. The company has three programs in sustained release, as well as three programs for site-specific delivery, oral peptide/protein delivery and mucosal protection from the effects of non-steroidal anti-inflammatory drugs

Read the full 832 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE